RxDoctor Payments Data

Arshjyot Narula, MD

Internal Medicine · Pittsburgh, PANPI 1831477827

Payments from drug & device makers

$3,695in general payments, 2019–2025

Across 209 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$736
  • Lilly USA, LLC$424
  • AbbVie$364
  • Johnson & Johnson$304
  • Daiichi Sankyo Inc.$288
  • Pfizer$248
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,688100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,695 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,541
Medicare patients
215
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$84,378
JardianceEmpagliflozin75$81,949
EliquisApixaban83$63,782
MounjaroTirzepatide35$35,194
TrulicityDulaglutide22$29,271
XareltoRivaroxaban19$21,723
Repatha SureclickEvolocumab18$9,757
Breo ElliptaFluticasone/Vilanterol17$9,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,845
Atorvastatin Calcium447$4,051
Levothyroxine Sodium380$3,423
Potassium Chloride41$2,482
SynthroidLevothyroxine Sodium51$2,056
Bupropion Hcl44$1,843
Famotidine135$1,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$736$84,37882 claims
Boehringer IngelheimJardiance$84$81,94975 claims
Lilly USA, LLCMounjaro, Trulicity$424$64,46557 claims
PfizerEliquis$248$63,78283 claims
Johnson & JohnsonXarelto$304$21,72319 claims
GSKBreo Ellipta, Trelegy Ellipta$136$18,60131 claims
AbbVieSynthroid$364$2,05651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →